Literature DB >> 12671144

Tuberculin testing and risk of tuberculosis infection among New York City schoolchildren.

Celine R Gounder1, Cynthia R Driver, Jerod N Scholten, Huimin Shen, Sonal S Munsiff.   

Abstract

OBJECTIVES: To assess adherence to a 1996 health policy change, which discontinued mandatory tuberculin skin testing (TST) of new entrants to NYC primary schools and continued mandatory testing of new entrants to secondary schools.
METHODS: The proportion tested before (1991-1995) and after (1996-1998) the change in health policy was determined. Factors associated with TST positivity and the cost of continued testing were assessed.
RESULTS: A total of 76.6% of 551 636 new entrants to primary schools were tested in 1991-1995; slightly fewer, 71.1% of 339 958, were tested in 1996- 1998. Among new entrants to secondary schools, 31.0% of 106 463 were tested in 1991-1995 and 51.4% of 53 762 were tested in 1996-1998. The proportion who were TST-positive continued to decrease after 1996 to 1.2% among primary and 9.7% among secondary schoolchildren in 1998. Older age and birth outside the United States were associated with TST positivity. The estimated minimum cost of continued testing in primary schools was $123 152 per tuberculosis case prevented.
CONCLUSION: An approach aimed at reducing testing of children at low risk for latent tuberculosis infection did not decrease testing of younger children. More important, older children who were more likely to be born in countries of high tuberculosis incidence were not tested. Additional efforts are needed to increase awareness among medical and school personnel to decrease testing among children who do not have risk factors for latent tuberculosis infection and to increase tuberculin testing of children who are entering school for the first time at the secondary level and do have risk factors for tuberculosis infection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12671144     DOI: 10.1542/peds.111.4.e309

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  7 in total

1.  Impact of targeted testing for latent tuberculosis infection using commercially available diagnostics.

Authors:  James D Mancuso; David Tribble; Gerald H Mazurek; Yuanzhang Li; Cara Olsen; Naomi E Aronson; Lawrence Geiter; Donald Goodwin; Lisa W Keep
Journal:  Clin Infect Dis       Date:  2011-08-01       Impact factor: 9.079

2.  Cost-effectiveness of latent tuberculosis screening before steroid therapy for idiopathic nephrotic syndrome in children.

Authors:  Benjamin L Laskin; Jens Goebel; Jeffrey R Starke; Daniel P Schauer; Mark H Eckman
Journal:  Am J Kidney Dis       Date:  2012-07-10       Impact factor: 8.860

Review 3.  Tuberculosis: evidence review for newly arriving immigrants and refugees.

Authors:  Christina Greenaway; Amelia Sandoe; Bilkis Vissandjee; Ian Kitai; Doug Gruner; Wendy Wobeser; Kevin Pottie; Erin Ueffing; Dick Menzies; Kevin Schwartzman
Journal:  CMAJ       Date:  2010-07-15       Impact factor: 8.262

4.  Practices and policies of providers testing school-aged children for tuberculosis, Connecticut, 2008.

Authors:  Christina M Lazar; Lynn Sosa; Mark N Lobato
Journal:  J Community Health       Date:  2010-10

5.  Tuberculin skin testing in children.

Authors:  Marina Reznik; Philip O Ozuah
Journal:  Emerg Infect Dis       Date:  2006-05       Impact factor: 6.883

6.  Tuberculosis in Internationally Displaced Children Resettling in Harris County, Texas, USA, 2010-20151.

Authors:  Gabriella S Lamb; Andrea T Cruz; Elizabeth A Camp; Michelle Javier; Jessica Montour; Tamisha Piper; Umair A Shah; Jeffrey R Starke
Journal:  Emerg Infect Dis       Date:  2020-08       Impact factor: 6.883

7.  Recommendations for the screening of paediatric latent tuberculosis infection in indigenous communities: a systematic review of screening strategies among high-risk groups in low-incidence countries.

Authors:  Lena Faust; Anne McCarthy; Yoko Schreiber
Journal:  BMC Public Health       Date:  2018-08-06       Impact factor: 3.295

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.